Literature DB >> 30699352

Persistence of Integrase-Deficient Lentiviral Vectors Correlates with the Induction of STING-Independent CD8+ T Cell Responses.

Céline Cousin1, Marine Oberkampf1, Tristan Felix1, Pierre Rosenbaum1, Robert Weil2, Sylvie Fabrega3, Valeria Morante4, Donatella Negri4, Andrea Cara5, Gilles Dadaglio6, Claude Leclerc7.   

Abstract

Lentiviruses are among the most promising viral vectors for in vivo gene delivery. To overcome the risk of insertional mutagenesis, integrase-deficient lentiviral vectors (IDLVs) have been developed. We show here that strong and persistent specific cytotoxic T cell (CTL) responses are induced by IDLVs, which persist several months after a single injection. These responses were associated with the induction of mild and transient maturation of dendritic cells (DCs) and with the production of low levels of inflammatory cytokines and chemokines. They were independent of the IFN-I, TLR/MyD88, interferon regulatory factor (IRF), retinoic acid induced gene I (RIG-I), and stimulator of interferon genes (STING) pathways but require NF-κB signaling in CD11c+ DCs. Despite the lack of integration of IDLVs, the transgene persists for 3 months in the spleen and liver of IDLV-injected mice. These results demonstrate that the capacity of IDLVs to trigger persistent adaptive responses is mediated by a weak and transient innate response, along with the persistence of the vector in tissues.
Copyright © 2019 Institut Pasteur. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  antigen persistence; cytotoxic T cell responses; innate pathways; integrase-deficient lentiviral vectors; memory; pattern recognition receptors; vaccines

Mesh:

Substances:

Year:  2019        PMID: 30699352      PMCID: PMC6679900          DOI: 10.1016/j.celrep.2019.01.025

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  70 in total

1.  A role for IL-5 in the induction of cytotoxic T lymphocytes in vivo.

Authors:  V Apostolopoulos; I F McKenzie; C Lees; K I Matthaei; I G Young
Journal:  Eur J Immunol       Date:  2000-06       Impact factor: 5.532

2.  Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance.

Authors:  Hans Christian Probst; Jacques Lagnel; George Kollias; Maries van den Broek
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

3.  Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9.

Authors:  Andreas Pichlmair; Sandra S Diebold; Stephen Gschmeissner; Yasuhiro Takeuchi; Yasuhiro Ikeda; Mary K Collins; Caetano Reis e Sousa
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

4.  HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.

Authors:  Karine Breckpot; David Escors; Frederick Arce; Lucienne Lopes; Katarzyna Karwacz; Sandra Van Lint; Marleen Keyaerts; Mary Collins
Journal:  J Virol       Date:  2010-03-17       Impact factor: 5.103

5.  Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual.

Authors:  Melissa Swiecki; Susan Gilfillan; William Vermi; Yaming Wang; Marco Colonna
Journal:  Immunity       Date:  2010-12-02       Impact factor: 31.745

6.  Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.

Authors:  Hiroaki Hemmi; Tsuneyasu Kaisho; Osamu Takeuchi; Shintaro Sato; Hideki Sanjo; Katsuaki Hoshino; Takao Horiuchi; Hideyuki Tomizawa; Kiyoshi Takeda; Shizuo Akira
Journal:  Nat Immunol       Date:  2002-01-22       Impact factor: 25.606

7.  Activation of NF-kappa B by the dsRNA-dependent protein kinase, PKR involves the I kappa B kinase complex.

Authors:  J Gil; J Alcamí; M Esteban
Journal:  Oncogene       Date:  2000-03-09       Impact factor: 9.867

8.  Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy.

Authors:  Katarzyna Karwacz; Sayandip Mukherjee; Luis Apolonia; Michael P Blundell; Gerben Bouma; David Escors; Mary K Collins; Adrian J Thrasher
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

9.  Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques.

Authors:  Anne-Sophie Beignon; Karine Mollier; Christelle Liard; Frédéric Coutant; Sandie Munier; Julie Rivière; Philippe Souque; Pierre Charneau
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

10.  Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy.

Authors:  Nathalie Cartier; Salima Hacein-Bey-Abina; Cynthia C Bartholomae; Gabor Veres; Manfred Schmidt; Ina Kutschera; Michel Vidaud; Ulrich Abel; Liliane Dal-Cortivo; Laure Caccavelli; Nizar Mahlaoui; Véronique Kiermer; Denice Mittelstaedt; Céline Bellesme; Najiba Lahlou; François Lefrère; Stéphane Blanche; Muriel Audit; Emmanuel Payen; Philippe Leboulch; Bruno l'Homme; Pierre Bougnères; Christof Von Kalle; Alain Fischer; Marina Cavazzana-Calvo; Patrick Aubourg
Journal:  Science       Date:  2009-11-06       Impact factor: 47.728

View more
  10 in total

1.  Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles.

Authors:  Xuefeng Li; Sina Khorsandi; Yifan Wang; Julien Santelli; Kristin Huntoon; Nhu Nguyen; Mingming Yang; DaeYong Lee; Yifei Lu; Ruoqi Gao; Betty Y S Kim; Caroline de Gracia Lux; Robert F Mattrey; Wen Jiang; Jacques Lux
Journal:  Nat Nanotechnol       Date:  2022-05-30       Impact factor: 40.523

2.  Skeletal Muscle Is an Antigen Reservoir in Integrase-Defective Lentiviral Vector-Induced Long-Term Immunity.

Authors:  Yi-Yu Lin; Ian Belle; Maria Blasi; Min-Nung Huang; Anne F Buckley; Wes Rountree; Mary E Klotman; Andrea Cara; Donatella Negri
Journal:  Mol Ther Methods Clin Dev       Date:  2020-03-13       Impact factor: 6.698

3.  Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs.

Authors:  Maria Blasi; Donatella Negri; Kevin O Saunders; Erich J Baker; Hannah Stadtler; Celia LaBranche; Benjamin Mildenberg; Georgeanna Morton; Andrew Ciarla; Xiaoying Shen; Yunfei Wang; Wes Rountree; Bala Balakumaran; Sampa Santra; Barton F Haynes; Anthony M Moody; Andrea Cara; Mary E Klotman
Journal:  NPJ Vaccines       Date:  2020-11-18       Impact factor: 7.344

4.  Integrase-Defective Lentiviral Vectors for Delivery of Monoclonal Antibodies against Influenza.

Authors:  Zuleika Michelini; Judith M Minkoff; Jianjun Yang; Donatella Negri; Andrea Cara; Brendon J Hanson; Mirella Salvatore
Journal:  Viruses       Date:  2020-12-17       Impact factor: 5.048

5.  Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.

Authors:  Min-Wen Ku; Pierre Authié; Maryline Bourgine; François Anna; Amandine Noirat; Fanny Moncoq; Benjamin Vesin; Fabien Nevo; Jodie Lopez; Philippe Souque; Catherine Blanc; Ingrid Fert; Sébastien Chardenoux; Llta Lafosse; Delphine Cussigh; David Hardy; Kirill Nemirov; Françoise Guinet; Francina Langa Vives; Laleh Majlessi; Pierre Charneau
Journal:  EMBO Mol Med       Date:  2021-10-25       Impact factor: 12.137

6.  An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.

Authors:  Benjamin Vesin; Jodie Lopez; Amandine Noirat; Pierre Authié; Ingrid Fert; Fabien Le Chevalier; Fanny Moncoq; Kirill Nemirov; Catherine Blanc; Cyril Planchais; Hugo Mouquet; Françoise Guinet; David Hardy; Francina Langa Vives; Christiane Gerke; François Anna; Maryline Bourgine; Laleh Majlessi; Pierre Charneau
Journal:  Mol Ther       Date:  2022-04-27       Impact factor: 12.910

7.  Integrase deficient lentiviral vector: prospects for safe clinical applications.

Authors:  Chee-Hong Takahiro Yew; Narmatha Gurumoorthy; Fazlina Nordin; Gee Jun Tye; Wan Safwani Wan Kamarul Zaman; Jun Jie Tan; Min Hwei Ng
Journal:  PeerJ       Date:  2022-08-12       Impact factor: 3.061

8.  A lentiviral vector expressing a dendritic cell-targeting multimer induces mucosal anti-mycobacterial CD4+ T-cell immunity.

Authors:  François Anna; Jodie Lopez; Fanny Moncoq; Catherine Blanc; Pierre Authié; Amandine Noirat; Ingrid Fert; Philippe Souque; Fabien Nevo; Alexandre Pawlik; David Hardy; Sophie Goyard; Denis Hudrisier; Roland Brosch; Françoise Guinet; Olivier Neyrolles; Pierre Charneau; Laleh Majlessi
Journal:  Mucosal Immunol       Date:  2022-09-14       Impact factor: 8.701

Review 9.  An Update on the HIV DNA Vaccine Strategy.

Authors:  Joseph Hokello; Adhikarimayum Lakhikumar Sharma; Mudit Tyagi
Journal:  Vaccines (Basel)       Date:  2021-06-05

10.  Lentiviral vector induces high-quality memory T cells via dendritic cells transduction.

Authors:  Min Wen Ku; Pierre Authié; Fabien Nevo; Philippe Souque; Maryline Bourgine; Marta Romano; Pierre Charneau; Laleh Majlessi
Journal:  Commun Biol       Date:  2021-06-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.